The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Three private biotechs enter clinical trials, one targeting KRAS.
